Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis.
We studied the serum levels of receptor activator of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), pro-matrix metalloproteinase (MMP) 1, MMP3, and tissue inhibitor of metalloproteinase (TIMP) 1 in patients with juvenile idiopathic arthritis (JIA) and correlated these with different disease variables. Sera of 70 patients with JIA (ILAR 2001 criteria) and 33 age- and sex-matched controls were assayed by enzyme-linked immunosorbent assay. Nonparametric tests were used for analysis of data. The subtype distribution of the JIA patients was: enthesitis-related arthritis (ERA) 24, polyarticular 22, systemic onset 13, oligoarticular 8, and others 3. The median level of RANKL, OPG, pro-MMP1, MMP3, and TIMP-1 were elevated in JIA patients as compared to controls (p < 0.001). There was no difference in levels among different types of JIA. RANKL/OPG ratio was elevated in all subtypes of JIA. MMP3/TIMP-1 ratio correlated with measures of disease activity including swollen and tender joint count, erythrocyte sedimentation rate, and disease activity score (rS 0.28, p < 0.05). Ours is the first study to show elevated RANKL in serum of patients with JIA. Further, our data suggest that patients with ERA have similar levels to other forms of JIA. Association of the MMP3/TIMP-1 ratio with disease activity suggests that it may be a useful biomarker for follow-up.
Sarma
Pradip Kumar
PK
Department of Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Misra
Ramnath
R
Aggarwal
Amita
A
D000293:Adolescent; D000328:Adult; D001171:Arthritis, Juvenile / Q000097:blood* / Q000145:classification / Q000503:physiopathology; D015415:Biomarkers; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000097:blood*; D019278:Matrix Metalloproteinase 3 / Q000097:blood*; D053244:Osteoprotegerin / Q000097:blood*; D053245:RANK Ligand / Q000097:blood*; D012720:Severity of Illness Index; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood*
D015415:Biomarkers; D053244:Osteoprotegerin; D053245:RANK Ligand; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; D019715:Tissue Inhibitor of Metalloproteinase-1; D019278:Matrix Metalloproteinase 3; D020781:Matrix Metalloproteinase 1
Biochem Biophys Res Commun. 2000 Sep 7;275(3):768-75
10973797
J Rheumatol. 2000 Apr;27(4):888-93
10782811
Rheumatology (Oxford). 2005 Nov;44(11):1383-9
16049050
Rheumatology (Oxford). 2003 Jan;42(1):83-8
12509618
Ann Rheum Dis. 2000 Jun;59(6):455-61
10834863
J Rheumatol. 2002 Apr;29(4):826-31
11950028
J Rheumatol Suppl. 2000 Apr;58:34-7
10782854
Arthritis Rheum. 2005 Jul;52(7):2092-102
15986372
J Rheumatol. 2006 Aug;33(8):1523-9
16881109
J Rheumatol. 2004 Feb;31(2):390-2
14760812
J Rheumatol. 2006 Aug;33(8):1642-5
16881120
Arthritis Rheum. 2002 Jul;46(7):1744-53
12124857
Arthritis Rheum. 2001 Feb;44(2):253-9
11229454
Arthritis Rheum. 2006 May;54(5):1602-7
16646003
J Rheumatol. 2004 May;31(5):986-91
15124262